- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about REGN
Recent news which mentions REGN
From Benzinga
From Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
From Benzinga
These Promising Clinical Results Could Be Huge for Amgen Investors
September 11, 2021
From Motley Fool
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
September 11, 2021
From Motley Fool
3 Stocks to Watch in September
September 10, 2021
From Motley Fool
Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?
September 09, 2021
From Motley Fool
3 Hot Stocks to Buy in September
September 07, 2021
From Motley Fool
3 Biotech Stocks That Soared to New Heights Last Week
September 05, 2021
From Motley Fool
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
September 02, 2021
From Benzinga
3 Biotech Stocks That Are Too Cheap to Ignore
September 02, 2021
From Motley Fool
Now May Be the Big Moment for These 2 COVID Stocks
September 02, 2021
From Motley Fool
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
From Benzinga
Could CRISPR Therapeutics Stock Help You Retire a Millionaire?
August 31, 2021
From Motley Fool
From Benzinga
Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential
August 30, 2021
From Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
August 30, 2021
From Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
August 30, 2021
From Benzinga
7 Best ETFs to Buy to Cover a Broad Spectrum of Opportunities
August 27, 2021
From InvestorPlace
From Motley Fool
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
From Benzinga
3 Growth Stocks Near Record Highs That Are Still Worth Buying
August 27, 2021
From Motley Fool
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
August 24, 2021
From Benzinga
From Benzinga
4 Reasons I Just Bought Ocular Therapeutix Stock
August 21, 2021
From Motley Fool
Stocks That Hit 52-Week Highs On Friday
August 20, 2021
From Benzinga
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
August 20, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.